⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
globenewswire.com
IONS
Next Generation Drug Conjugates Market Trends and Global Forecasts, 2025-2035 - Lutathera, Pluvicto, Givlaari, Oxlumo, Leqvio, and Amvuttra Represent Milestones in Advanced Treatment Solutions - ResearchAndMarkets.com
businesswire.com
NVS
ALNY
ARWR
GERN
IONS
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica
globenewswire.com
PFE
ALNY
IONS
JNJ
TSE
GEHC
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
businesswire.com
IONS
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
COLL
$15.5 Bn Next Generation Drug Conjugates Market Trends and Global Forecasts, 2035
globenewswire.com
ALNY
ARWR
GERN
IONS
n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases USA - English USA - English USA - Français USA - Deutsch
prnewswire.com
IONS
n-Lorem und EspeRare kündigen europäische Zusammenarbeit zur Erweiterung des Zugangs zu individualisierten ASO-Therapien für seltene genetische Erkrankungen an USA - Deutsch USA - English USA - Français
prnewswire.com
IONS
n-Lorem and EspeRare annoncent une collaboration européenne pour élargir l'accès aux thérapies ASO individualisées pour les maladies génétiques rares USA - Français USA - English USA - Deutsch
prnewswire.com
IONS